Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors - A Southwest Oncology Group trial

Sarah A. Taylor, John Crowley, F. Stephen Vogel, Jeannette J. Townsend, Harmon J. Eyre, Kurt A. Jaeckle, Harry E. Hynes, Jerry T. Guy

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Twenty-three patients with malignant central nervous system tumors were treated with fludarabine phosphate (2-FAMP) on a 5 day bolus schedule. One brief partial response was observed in 20 malignant astrocytoma patients. 2FAMP as given in this protocol is inactive in previously treated patients with recurrent malignant astrocytomas.

Original languageEnglish (US)
Pages (from-to)195-197
Number of pages3
JournalInvestigational New Drugs
Volume9
Issue number2
DOIs
StatePublished - May 1 1991

    Fingerprint

Keywords

  • central nervous system tumors
  • fludarabine phosphate
  • phase II

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Taylor, S. A., Crowley, J., Vogel, F. S., Townsend, J. J., Eyre, H. J., Jaeckle, K. A., Hynes, H. E., & Guy, J. T. (1991). Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors - A Southwest Oncology Group trial. Investigational New Drugs, 9(2), 195-197. https://doi.org/10.1007/BF00175089